Trial Profile
A Prospective, Randomized, Controlled Clinical Trial to Evaluate the Role of Peg-IFN Alfa-2a in Reducing RelapSe Rate in Patients With Hepatitis B e Antigen(HBeAg)-nEgative Chronic Hepatitis B After Discontinuation of NUC Therapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Nov 2022
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- 27 Oct 2022 Status changed from recruiting to completed.
- 11 Apr 2017 Status changed from not yet recruiting to recruiting.
- 06 Nov 2015 New trial record